Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 87.68 CHF 1.11% Market Closed
Market Cap: 171.5B CHF
Have any thoughts about
Novartis AG?
Write Note

Novartis AG
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Novartis AG
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Novartis AG
SIX:NOVN
Net Income (Common)
$17.6B
CAGR 3-Years
22%
CAGR 5-Years
8%
CAGR 10-Years
5%
Roche Holding AG
SIX:ROG
Net Income (Common)
CHf11.5B
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
0%
S
Sandoz Group AG
SIX:SDZ
Net Income (Common)
$77m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novartis AG
Glance View

Market Cap
171.5B CHF
Industry
Pharmaceuticals

Nestled in the heart of Europe's pharmaceutical landscape, Novartis AG has firmly etched its presence as a beacon of innovation and scientific prowess. This Swiss multinational behemoth, headquartered in Basel, operates at the confluence of research-driven development and cutting-edge technology. At its core, Novartis is devoted to discovering novel therapeutics and delivering them to patients across the globe. The company’s operations span various segments, with Pharmaceuticals and Oncology standing as the pillars of its revenue model. Through these divisions, Novartis vigorously pursues advancements in the treatment of diseases, focusing on areas such as cardiovascular, immunology, neuroscience, respiratory, and oncology. The innovative medicines they develop emerge from robust pipelines bolstered by strategic investments in research and development, propelling them to the forefront of healthcare innovation. Moreover, Novartis leverages a synergy between its Sandoz division, which is known for a strong generics and biosimilars portfolio, and its advanced therapeutic areas in Pharmaceuticals. This duality not only makes the company versatile but also resilient in the face of market volatilities. Unlike many pharmaceutical giants, Novartis prioritizes a hybrid approach by combining cutting-edge biotechnology with a stronghold in cost-effective generics. This model allows Novartis to cater to both the high-margin, innovation-driven segments and the volume-based, lower-margin arenas. Ultimately, their strategic focus is not just on creating the next blockbuster drug but on improving access to healthcare solutions globally, thereby reinforcing its revenue engine while delivering on its mission to reimagine medicine.

NOVN Intrinsic Value
97.92 CHF
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Novartis AG's Net Income (Common)?
Net Income (Common)
17.6B USD

Based on the financial report for Sep 30, 2024, Novartis AG's Net Income (Common) amounts to 17.6B USD.

What is Novartis AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%

Over the last year, the Net Income (Common) growth was 74%. The average annual Net Income (Common) growth rates for Novartis AG have been 22% over the past three years , 8% over the past five years , and 5% over the past ten years .

Back to Top